休斯顿，德克萨斯州 — 专门从事治疗制剂的制药公司Coya Therapeutics, Inc. (NASDAQ:COYA)于2024年11月1日宣布，Hideki Garren博士即刻从其董事会辞职。这一消息在最近提交给美国证券交易委员会的文件中披露。 根据文件显示，Garren博士的辞职并非由于与公司的运营、政策或实践有任何分歧。相反，这是为了遵守其新雇主的政策，该政策限制员工在开发与雇主涉及 ...
Coya Therapeutics, Inc. ( (COYA) ) has released its Q3 earnings. Here is a breakdown of the information Coya Therapeutics, Inc. presented to ...
October 25, 2024, 17:38 pm ET, BY Thomas H. Kee Jr- Editor, Stock Traders Daily| Editor: Thomas H. Kee Jr. ( Follow on ...
Coya Therapeutics, Inc. ( (COYA) ) just unveiled an update. Coya Therapeutics, a clinical-stage biotech firm, reported positive outcomes from ...
9 天on MSN
Coya Therapeutics said on Tuesday its experimental Alzheimer's drug was safe and increased levels of a type of immune cells ...
Coya (COY) stock tumbled 23% Tuesday on mixed results from a Phase 2 clinical trial of its therapy candidate LD IL-2 in the ...
Coya Therapeutics, Inc. (Nasdaq: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, provides a ...
On Tuesday, Coya Therapeutics, Inc. (NASDAQ:COYA) released results from the placebo-controlled Phase 2 trial of LD IL-2 in ...
Alireza Faridar, M.D., a neurologist at Houston Methodist Hospital, looked at (PDF) the IL-2 component of the combination in an investigator-initiated trial. The study randomized 38 people with mild ...
Arun Swaminathan assumes new role as chief executive officer of Coya Therapeutics: Houston Tuesday, November 5, 2024, 11:00 ...
While phase II results of Coya Therapeutics Inc.’s low-dose IL-2 drug, COYA-301, showed promise in Alzheimer’s disease patients when dosed every four weeks, it was the more frequent dosing of every ...
HOUSTON - Coya Therapeutics, Inc. (NASDAQ: COYA) has announced positive outcomes from a Phase 2 clinical trial for low-dose interleukin-2 (LD IL-2) in treating mild to moderate Alzheimer's Disease.
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈